Atlanta VA Medical Center, Decatur, GA; Nutrition and Health Sciences, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA.
Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA.
J Diabetes Complications. 2017 Sep;31(9):1430-1436. doi: 10.1016/j.jdiacomp.2017.06.001. Epub 2017 Jun 6.
Clinical trials show lifestyle change programs are beneficial, yet large-scale, successful translation of these programs is scarce. We investigated the association between participation in the largest U.S. lifestyle change program, MOVE!, and diabetes control outcomes.
This longitudinal, retrospective cohort study used Veterans Health Administration databases of patients with diabetes who participated in MOVE! between 2005 and 2012, or met eligibility criteria (BMI ≥25kg/m) but did not participate. Main outcomes were diabetic eye disease, renal disease, and medication intensification.
There were 400,170 eligible patients with diabetes, including 87,366 (22%) MOVE!
Included patients were 96% male, 77% white, with mean age 58years and BMI 34kg/m. Controlling for baseline measurements and age, race, sex, BMI, and antidiabetes medications, MOVE! participants had lower body weight (-0.6kg), random plasma glucose (-2.8mg/dL), and HbA1c (-0.1%) at 12months compared to nonparticipants (each p<0.001). In multivariable Cox models, MOVE! participants had lower incidence of eye disease (hazard ratio 0.80, 95% CI 0.75-0.84) and renal disease (HR 0.89, 95% CI 0.86-0.92) and reduced medication intensification (HR 0.82, 95% CI 0.80-0.84).
If able to overcome participation challenges, lifestyle change programs in U.S. health systems may improve health among the growing patient population with diabetes.
临床试验表明生活方式改变计划是有益的,但这些计划的大规模成功转化却很少见。我们调查了参与美国最大的生活方式改变计划 MOVE!与糖尿病控制结果之间的关系。
这是一项纵向、回顾性队列研究,使用退伍军人健康管理局的数据库,对 2005 年至 2012 年间参加 MOVE!的糖尿病患者或符合资格标准(BMI≥25kg/m)但未参加的患者进行了研究。主要结果是糖尿病眼病、肾病和药物强化。
有 400170 名符合条件的糖尿病患者,其中 87366 名(22%)参加了 MOVE!
包括患者 96%为男性,77%为白人,平均年龄为 58 岁,BMI 为 34kg/m。在控制基线测量值和年龄、种族、性别、BMI 和抗糖尿病药物后,与非参与者相比,MOVE!参与者在 12 个月时体重减轻(-0.6kg)、随机血浆葡萄糖(-2.8mg/dL)和 HbA1c(-0.1%)(均<0.001)。在多变量 Cox 模型中,MOVE!参与者的眼病发病率较低(风险比 0.80,95%CI 0.75-0.84)和肾病(HR 0.89,95%CI 0.86-0.92)以及药物强化减少(HR 0.82,95%CI 0.80-0.84)。
如果能够克服参与挑战,美国卫生系统中的生活方式改变计划可能会改善不断增长的糖尿病患者群体的健康状况。